EBV

EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001

Retrieved on: 
星期一, 十二月 4, 2023
Guillain–Barré syndrome, Infection, Inflammatory bowel disease, CMO, Multiple sclerosis, Vaccine, Disease, Virus-like particle, Mouse, Human, GMP, EBV, Cancer, Epithelium, CSO, Chronic fatigue syndrome, Epstein–Barr virus, Infectious mononucleosis

The presented data demonstrate that even at low concentrations, non-adjuvanted EBV-001 induces a specific and strong B cell response in mice.

Key Points: 
  • The presented data demonstrate that even at low concentrations, non-adjuvanted EBV-001 induces a specific and strong B cell response in mice.
  • EBViously has generated positive preclinical proof-of-concept data on the immunogenicity of the vaccine candidate.
  • “In addition to a strong preclinical data package, we now have everything in place for the start of clinical trials,” said Axel Polack, M.D., designated CEO of EBViously.
  • It is also known that people infected with EBV are 32 times more likely to develop multiple sclerosis.

Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Associa

Retrieved on: 
星期二, 十一月 28, 2023
Plenary session, NPC, Food, Survival, Risk, ASCO, CHRS, HKEX, FDA, PD-1, Progression-free survival, Incidence, Society, Cisplatin, Cancer, UPMC Hillman Cancer Center, Annual general meeting, American Medical Association, Death, UPMC, Nature Medicine, Sun, EBV, Patient, OS, PFS, Journal, Development, PD-L1, GP, Pharmaceutical industry

REDWOOD CITY, Calif. And SHANGHAI, China, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180) announced today the publication of the final overall survival (OS) results from the pivotal JUPITER-02 study (NCT03581786), a randomized, double-blind, placebo-controlled, international, multi-center Phase 3 clinical trial evaluating the immune checkpoint inhibitor LOQTORZI™ (toripalimab-tpzi), in combination with the chemotherapy agents gemcitabine and cisplatin, as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) in the Journal of the American Medical Association (JAMA). As previously reported at the 2023 American Society of Clinical Oncologists (ASCO) Annual Meeting, the final analysis revealed a 37% reduction in the risk of death in NPC patients treated with toripalimab plus chemotherapy versus chemotherapy alone.

Key Points: 
  • Coherus plans to launch LOQTORZI in the United States in January 2024.
  • “There are limited options for patients living with this aggressive head and neck cancer.
  • The median OS was not reached in the LOQTORZI arm and was 33.7 months in the placebo arm.
  • The safety profile was consistent with that previously reported in other toripalimab clinical trials and consistent with the PD-1 inhibitor class.

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

Retrieved on: 
星期一, 十一月 27, 2023
Recce, Ross River virus, Simplex, ASX, Government, RCE, Klebsiella pneumoniae, PCT, Virus, Burn, Administration, Streptococcus pneumoniae, Patent, Disease, Staphylococcus aureus, Infection, Gonorrhea, Canada Revenue Agency, Inhalation, Shingles, Pseudomonas aeruginosa, Biology, COVID-19, Streptococcus pyogenes, Viral, EBV, Escherichia coli, HIV, Coronavirus, SARS-CoV-2, Cytomegalovirus, Staphylococcus, Urinary tract infection, Bacteria, Neisseria meningitidis, HCMV, Science, Skin, Pharmaceutical industry

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • In July 2023, the Company received an AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
  • The program is administered by the Canada Revenue Agency and is aimed at incentivizing businesses to conduct R&D in Canada, encouraging innovation and technological advancements.

Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories

Retrieved on: 
星期三, 十二月 20, 2023
Oncology, Health, Stem Cells, Clinical Trials, Research, Science, Biotechnology, Partnership, Food, FDA, PTLD, Trial of the century, Lymphoproliferative disorders, Biologics license application, Cancer, ATRA, USD, EBV, Patient, CD19, Epstein–Barr virus, BLA, Pharmaceutical industry

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM).

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM).
  • Building on the earlier partnership announced in October 2021 to commercialize tab-cel in Europe, this transaction provides Pierre Fabre Laboratories with the development, manufacturing, and commercialization rights for tab-cel in the United States and all remaining markets.
  • In addition, Pierre Fabre Laboratories will reimburse Atara for expected tab-cel global development costs through the Biologics License Application (BLA) transfer, and purchase future tab-cel inventory through the manufacturing transfer date.
  • Substantially all tab-cel manufacturing, clinical, and regulatory activities are planned to transition from Atara to Pierre Fabre Laboratories at the time of BLA transfer.

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Retrieved on: 
星期一, 十二月 11, 2023
Biotechnology, Pharmaceutical, Health, ATRA, Epstein–Barr virus, TCR, Gene editing, Phenotype, Lymphoid leukemia, ASH, IND, Risk, Northwest Biotherapeutics, B-cell lymphoma, HCT, Head, Patient, CD19, Autoimmune disease, Acute lymphoblastic leukemia, HLA, Cancer, Survival, CD20, EBV, Society, Cell, Vaccine, Atara

Findings support ATA3431 advancement into clinical testing, initially focused on the treatment of B-cell malignancies.

Key Points: 
  • Findings support ATA3431 advancement into clinical testing, initially focused on the treatment of B-cell malignancies.
  • The data will be presented in a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place December 9-12, 2023, in San Diego.
  • ATA3431 also incorporates the clinically validated 1XX costimulatory domain that enhances stemness and modulates exhaustion to extend functional persistence.
  • Compared to an autologous CD20/CD19 CAR-T benchmark, the ATA3431 preclinical data demonstrate potent antitumor activity, long-term persistence, and superior tumor growth inhibition.

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期五, 十二月 1, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, ATRA, Epstein–Barr virus, Protalix BioTherapeutics, EBV, Patient, Employment, Compensated emancipation, Cancer, Pharmaceutical industry, Thermoplastic

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 27,000 restricted stock units of Atara’s common stock to three newly hired employees.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 27,000 restricted stock units of Atara’s common stock to three newly hired employees.
  • These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of December 1, 2023, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

Retrieved on: 
星期三, 十一月 29, 2023
Oncology, Health, Stem Cells, Clinical Trials, Research, Science, Biotechnology, CNS, ATRA, Epstein–Barr virus, Safety, Partial-response maximum-likelihood, PST, Disease, Northwest Biotherapeutics, ESMO, HCT, Patient, CET, ORR, SOT, Cancer, Symantec Endpoint Protection, PTLD, Neurotoxicity, Congress, Central nervous system, EBV, TTR, OS, PR, Vaccine, Pharmaceutical industry

These results will be presented as an oral session at the European Society for Medical Oncology Immuno-Oncology (ESMO I‑O) Annual Congress taking place December 6-8, 2023, in Geneva, Switzerland.

Key Points: 
  • These results will be presented as an oral session at the European Society for Medical Oncology Immuno-Oncology (ESMO I‑O) Annual Congress taking place December 6-8, 2023, in Geneva, Switzerland.
  • “We’re pleased to share new multicenter data, including the first results from our ongoing multicohort EBVision trial and first clinical trial report of treatment with tab-cel in the first line setting.
  • The estimated one-year overall survival (OS) rate was 70.6% (95% CI: 43.0, 86.6) for all patients.
  • Date & Time: December 7, 2023, at 2:15 - 3:45 p.m. CET / 5:15 - 6:45 a.m. PST

Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference

Retrieved on: 
星期三, 十一月 22, 2023
Oncology, Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, ATRA, Webcast, Epstein–Barr virus, EST, Northwest Biotherapeutics, EBV, Cancer, Patient, Conference, Pharmaceutical industry, Broadcasting

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:50 a.m. EST.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:50 a.m. EST.
  • A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com .
  • An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

Atara Biotherapeutics To Participate at the Stifel Healthcare Conference

Retrieved on: 
星期五, 十一月 10, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Webcast, ATRA, Epstein–Barr virus, PST, Northwest Biotherapeutics, Patient, Conference, Cancer, EST, EBV, Pharmaceutical industry, Broadcasting

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York on Tuesday, November 14, 2023 at 8:30 a.m. PST / 11:30 a.m. EST.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York on Tuesday, November 14, 2023 at 8:30 a.m. PST / 11:30 a.m. EST.
  • A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com .
  • An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Retrieved on: 
星期三, 十一月 8, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, ATRA, EDSS, CDI, Epstein–Barr virus, Biologics license application, PMS, Biomarker, Northwest Biotherapeutics, ASH, Partnership, MS, Disability, Cancer, Autoimmunity, EBV, Patient, BLA

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS).

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS).
  • The study did not meet the primary endpoint of confirmed disability improvement (CDI) by expanded disability status scale (EDSS) at 12 months compared to placebo.
  • In addition, fluid and imaging biomarkers did not provide further supportive evidence.
  • "We are surprised and deeply disappointed with the results of EMBOLD, particularly for the MS patient community which is in urgent need of new treatment options.